BofA/Merrill Lynch Upgrades Momenta Pharmaceuticals (MNTA) to Buy
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Underperform to Buy.
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $10.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Tesla (TSLA) to Buy on wind up of positive catalysts
- B.Riley Upgrades The Children's Place (PLCE) to Neutral
- Evercore ISI Upgrades First Solar (FSLR) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
